Xvivo Perfusion AB (XVIVO) AI Stock Analysis

• Market Cap: kr5.81B
• Dividend Yield: N/A
• Average Volume (3M): 159.84K
• Price to Earnings (P/E): 196.0
• Beta (1Y): 1.32
• Revenue Growth: 8.39%
• EPS Growth: -85.36%
• Country: SE
• Employees: 193
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.26
• Shares Outstanding: 31,499,470
• 10 Day Avg. Volume: 140,875
• 30 Day Avg. Volume: 159,845
• PEG Ratio: 1.14
• Price to Book (P/B): 7.14
• Price to Sales (P/S): 18.73
• P/FCF Ratio: -188.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr225.03
• Price Target Upside: 27.86% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: kr189.00 ▲(7.39% Upside)

Xvivo Perfusion AB's overall stock score reflects strong financial health and operational efficiency, but is tempered by valuation concerns and mixed technical indicators. The company's strategic initiatives and growth in specific segments are positive, yet challenges in regulatory approvals and market conditions pose risks.

Positive Factors

Abdominal Segment Growth

The strong growth in the Abdominal segment, especially in liver and kidney sales, indicates a robust demand and successful product adoption, enhancing long-term revenue potential.

Strategic U.S. Partnerships

Strategic partnerships in the U.S. expand service capabilities, potentially increasing market share and solidifying the company's competitive position in a key market.

Cash Flow Management

Positive cash flow management reflects the company's ability to maintain financial health and invest in growth opportunities, supporting long-term sustainability.

Negative Factors

Challenges in U.S. Lung Market

Slower growth in the U.S. lung market could limit revenue potential and impact the company's ability to capitalize on a significant segment of its business.

Delayed U.S. Heart Regulatory Approval

Delays in regulatory approval for heart products can postpone market entry, affecting revenue growth and competitive positioning in the U.S. market.

Paused U.S. Liver Trial

Pausing the U.S. liver trial may delay product availability and revenue generation, impacting the company's strategic plans in the liver transplantation market.

Xvivo Perfusion AB Business Overview & Revenue Model

Company Description

Xvivo Perfusion AB (XVIVO) is a medical technology company specializing in the preservation and perfusion of organs for transplantation. Based in Sweden, XVIVO develops innovative solutions aimed at improving organ viability and transplant outcomes. The company operates primarily in the healthcare sector, focusing on organ preservation systems, perfusion solutions, and advanced technologies that enhance the transplantation process. Key products include the XVIVO Perfusion System and a range of preservation solutions designed for various organ types, including lungs, kidneys, and hearts.

How the Company Makes Money

XVIVO generates revenue primarily through the sale of its organ preservation and perfusion products to hospitals, transplant centers, and organ procurement organizations. The company's revenue model is built on direct sales of its specialized medical devices and solutions, as well as recurring revenue from consumables used in the perfusion processes. Significant partnerships with healthcare institutions and collaborations with research organizations also contribute to its earnings, as they help to expand market reach and enhance product development. Additionally, XVIVO may benefit from grants, research funding, and strategic alliances that support its innovation efforts in organ transplantation technologies.

Xvivo Perfusion AB Financial Statement Overview

Summary

Xvivo Perfusion AB demonstrates strong financial health with robust gross margins and low leverage. However, challenges with declining revenue growth and net profit margins, along with historical volatility in free cash flow, pose risks. Despite these, the company maintains operational efficiency and a solid equity position.

Income Statement

Xvivo Perfusion AB shows strong gross profit margins consistently above 70%, indicating efficient cost management. However, the TTM (Trailing-Twelve-Months) data reveals a decline in revenue growth rate by 3.75%, which is a concern. The net profit margin has decreased from 20.94% in 2024 to 13.53% in the TTM, reflecting reduced profitability. Despite these challenges, the company maintains a solid EBIT and EBITDA margin, demonstrating operational efficiency.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.05 in the TTM, indicating low financial leverage and a strong equity position. The return on equity has decreased slightly to 5.29% in the TTM from 7.98% in 2024, but remains positive, showing the company's ability to generate returns on shareholders' investments. The equity ratio remains healthy, reflecting a stable financial structure.

Cash Flow

Xvivo Perfusion AB has shown improvement in free cash flow growth, with a 5.03% increase in the TTM. The operating cash flow to net income ratio is 0.49, indicating moderate cash generation from operations. However, the free cash flow to net income ratio is 1.0, suggesting that all net income is being converted into free cash flow, which is a positive sign. Despite these strengths, the historical volatility in free cash flow remains a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	813.59M	822.41M	597.54M	415.29M	258.39M	179.86M
Gross Profit	594.07M	616.41M	445.11M	296.96M	188.28M	132.97M
EBITDA	101.42M	272.97M	35.05M	39.21M	39.20M	-43.33M
Net Income	29.90M	172.18M	91.82M	18.43M	8.15M	-43.73M
Balance Sheet
Total Assets	2.38B	2.40B	2.20B	1.73B	1.54B	1.15B
Cash, Cash Equivalents and Short-Term Investments	279.94M	415.52M	546.09M	246.54M	398.70M	353.44M
Total Debt	124.53M	34.04M	31.44M	10.01M	5.72M	7.21M
Total Liabilities	283.45M	245.97M	250.57M	302.95M	257.15M	141.85M
Stockholders Equity	2.09B	2.16B	1.95B	1.43B	1.29B	1.01B
Cash Flow
Free Cash Flow	55.63M	-81.86M	-97.65M	-103.09M	-106.13M	-76.94M
Operating Cash Flow	76.22M	111.29M	46.29M	27.86M	-12.06M	-12.27M
Investing Cash Flow	-303.34M	-243.81M	-161.62M	-197.62M	-187.70M	-266.53M
Financing Cash Flow	72.41M	-10.90M	418.55M	-6.84M	234.61M	482.77M

Xvivo Perfusion AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 176.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XVIVO, the sentiment is Positive. The current price of 176 is below the 20-day moving average (MA) of 178.74, below the 50-day MA of 176.05, and below the 200-day MA of 238.98, indicating a neutral trend. The MACD of 1.65 indicates Negative momentum. The RSI at 55.39 is Neutral, neither overbought nor oversold. The STOCH value of 53.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XVIVO.

Xvivo Perfusion AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VITR	71 Outperform	kr18.07B	40.96	3.34%	0.82%	-1.29%	―
CEVI	68 Neutral	kr3.59B	23.72	17.89%	1.66%	1.53%	0.79%
GETI.B	66 Neutral	kr58.12B	28.30	6.91%	2.15%	6.74%	21.40%
XVIVO	63 Neutral	kr5.81B	195.95	1.32%	―	8.39%	-85.36%
PAX	52 Neutral	kr1.24B	194.62	1.41%	―	21.71%	-80.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SEDANA	48 Neutral	€1.04B	-26.10	-4.42%	―	13.48%	28.98%

Xvivo Perfusion AB Corporate Events

XVIVO Perfusion AB Reports Mixed Financial Results Amid Strategic Investments

XVIVO Perfusion AB reported a slight decline in net sales for the first nine months of 2025, with a 1% organic growth in local currencies. The company saw significant growth in its Abdominal business area, while the Thoracic segment experienced a decline, impacting overall performance. Despite this, the company maintained a strong gross margin of 74%, and continued to invest heavily in research and development, which affected its net profit and cash flow.